A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Non-Squamous Non-Small Cell Lung Cancer
DRUG: erlotinib [Tarceva]
Incidence of adverse events (AEs), Length of patient on study (length of time of patient on study determined by investigator)
Best Response Rate per investigator assessment, Length of patient on study (length of time of patient on study determined by investigator)|Time to Progression (TTP), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first|Overall survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first
This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.